Loading...

SCNI SCINAI IMMUNOTHERAPEUTICS LTD Investments/Divestments 8-K Filing

SCN

SCN

SCINAI IMMUNOTHERAPEUTICS LTD

(SCNI)

2023 8-K

Annual Meeting Notice

Acquisition Report

Private Placement Details

Corporate Acquisition Update

Nasdaq Notification

Innovation Support Boost

Acquisition Completed

Annual Meeting Results

2025 Results Report

Annual Meeting Notice

Board Resignations

Funding Award Announcement

Grant Application Update

Equity Purchase Agreement

Business Update Provided

Funding Announcement

Government Clearance

Financial Results Announcement

Acquisition Announcement

License Agreement Termination

Equity Purchase Agreement

Equity Purchase Agreement

Q3 2024 Results

Annual Meeting Results

Annual Meeting Notice

License Agreement

Financial Statements Update

Compliance Regained

Debt Restructuring

Equity Investment Agreement

Financial Update

Loan Restructuring Agreement

Shareholder Meeting Results

Correction Notice Issued

Shareholder Notice

Q1 2024 Results

Positive Trial Results

Shareholder Meeting Notice

Investment Update

Nasdaq Compliance Extended

Investment Conversion

Compliance Regained

Compliance Update

Financial Report Issued

Nasdaq Delisting Notice

Presentation Update

New Business Updates

Warrant Exercise Completion

Warrant Exercise Agreement

Warrant Exercise Announcement

License Agreement with Max-...

Resignation of Director

Disclosure of Investor Pres...

External Links:

BiondVax Pharmaceuticals entered into a License Agreement with Max-Planck-Innovation GmbH and University Medical Center Gottingen to develop and commercialize VHH antibodies targeting Interleukin-17 (IL-17) as treatments for all potential indications.

AI Assistant

SCINAI IMMUNOTHERAPEUTICS LTD

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.